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Background: The β-secretase, BACE1, cleaves APP to initiate generation of the β-amyloid peptide, Aβ, that comprises
amyloid plaques in Alzheimer’s disease (AD). Reducing BACE1 activity is an attractive therapeutic approach to AD, but
complete inhibition of BACE1 could have mechanism-based side-effects as BACE1−/− mice show deficits in axon
guidance, myelination, memory, and other neurological processes. Since BACE1+/− mice appear normal there is interest
in determining whether 50% reduction in BACE1 is potentially effective in preventing or treating AD. APP transgenic
mice heterozygous for BACE1 have decreased Aβ but the extent of reduction varies greatly from study to study. Here
we assess the effects of 50% BACE1 reduction on the widely used 5XFAD mouse model of AD.
Results: 50% BACE1 reduction reduces Aβ42, plaques, and BACE1-cleaved APP fragments in female, but not in male,
5XFAD/BACE1+/− mice. 5XFAD/BACE1+/+ females have higher levels of Aβ42 and steady-state transgenic APP than
males, likely caused by an estrogen response element in the transgene Thy-1 promoter. We hypothesize that higher
transgenic APP level in female 5XFAD mice causes BACE1 to no longer be in excess over APP so that 50% BACE1
reduction has a significant Aβ42 lowering effect. In contrast, the lower APP level in 5XFAD males allows BACE1 to be in
excess over APP even at 50% BACE1 reduction, preventing lowering of Aβ42 in 5XFAD/BACE1+/− males. We also
developed and validated a dot blot assay with an Aβ42-selective antibody as an accurate and cost-effective alternative
to ELISA for measuring cerebral Aβ42 levels.
Conclusions: 50% BACE1 reduction lowers Aβ42 in female 5XFAD mice only, potentially because BACE1 is not in
excess over APP in 5XFAD females with higher transgene expression, while BACE1 is in excess over APP in 5XFAD
males with lower transgene expression. Our results suggest that greater than 50% BACE1 inhibition might be necessary
to significantly lower Aβ, given that BACE1 is likely to be in excess over APP in the human brain. Additionally, in
experiments using the 5XFAD mouse model, or other Thy-1 promoter transgenic mice, equal numbers of male and
female mice should be used, in order to avoid artifactual gender-related differences.
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Alzheimer’s disease (AD) is characterized by two types
of pathological lesions: neurofibrillary tangles, which are
composed of hyperphosphorylated forms of the protein
Tau, and amyloid plaques, which consist of aggregations
of the peptide β-amyloid (Aβ). Cerebral accumulation of
Aβ, especially the 42-amino acid isoform Aβ42, is
thought to play a critical early role in the development
of AD [1,2], so there is great interest in decreasing Aβ* Correspondence: r-vassar@northwestern.edu
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unless otherwise stated.levels in the brain to prevent or treat AD. Aβ is gene-
rated by the sequential cleavage of Amyloid Precursor
Protein (APP) by β-secretase (BACE1) and γ-secretase.
APP transgenic mouse models of AD that are devoid of
BACE1 expression via BACE1 gene knockout (BACE1−/−
mice) fail to generate Aβ and lack the amyloid plaques
and cognitive impairments found in APP transgenic
mice that express both BACE1 alleles [3-7]. These re-
sults validated BACE1 as the major β-secretase enzyme
in the brain and suggested that inhibition of BACE1
could be of therapeutic benefit for AD (reviewed in [8]).
Indeed, BACE1 inhibitor drugs are currently being tested
in clinical trials in AD and mild cognitively impairedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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safety and efficacy of BACE1 inhibitor drugs are un-
known at present.
Initially, BACE1 null mice were reported to be healthy
with no obvious phenotype [5,10], but more extensive ana-
lysis revealed that they have subtle neurological abnorma-
lities [8,9]. Subsequent studies have found that BACE1
null mice have higher offspring mortality, decreased
myelination, impaired memory, hyperactivity, axon mis-
guidance, schizophrenia-like phenotypes, and increased
seizure activity, but these phenotypes are largely absent
from BACE1+/− mice [6,7,11-18]. The BACE1 substrates
responsible for some of these phenotypes are known, such
as the role of neuregulin in myelination [13,17] and CHL1
in axon guidance [18], but others remain unexplained.
Proteomic screens of BACE1−/− compared to BACE1+/+
primary neurons [19,20] have revealed even more potential
BACE1 substrates that are not yet validated in vivo but
could have a role in these phenotypes, and others yet to be
described.
Since complete loss of BACE1 activity has detrimental
effects in BACE1−/− mice it seems likely that almost
complete inhibition of BACE1 for treatment or preven-
tion of Alzheimer’s disease could have mechanism based
side-effects in humans. The 50% BACE1 reduction ob-
served in in BACE1+/− mice, on the other hand, seems
to have no ill effects. If 50% inhibition of BACE1 is able
to decrease Aβ production enough to delay disease onset
or slow disease progression, this could represent a
therapeutic strategy to avoid side effects of almost total
BACE1 inhibition. The BACE1+/− heterozygous null
mouse is a useful model for 50% BACE1 inhibition, and
several publications have described BACE1+/− mice on
various backgrounds of APP transgenic mouse models,
with most observing some reduction in Aβ levels, but
the degree of Aβ lowering varies from model to model
[5,14,21-26]. It is also unclear whether 50% reduction in
BACE1 leads to a long-lasting decrease in cerebral Aβ. It
has been reported in the PDAPP mouse model that
BACE1+/− genotype led to a small reduction in Aβ at
3 months of age, but dramatic Aβ decreases at 13 and
18 months [24]. On the other hand, in transgenic mice
co-expressing APP Swedish (swe) and presenilin 1 exon 9
deletion (PS1Δ9) familial AD (FAD) mutations, BACE1+/−
genotype led to decreased cerebral Aβ and plaques at
12 months, but not at 20 months of age [14].
This work extends the study of 50% BACE1 inhibition
as a therapeutic approach, demonstrating that 50% BACE1
reduction in 5XFAD transgenic mice, which display ag-
gressive, early onset amyloid pathology [27], decreases
Aβ42, plaques, and BACE1-cleaved APP fragments (C99
and sAPPβ) at 4, 6 and 9 months of age, but unexpectedly
only in females, which have higher levels of Aβ42 and
amyloid plaques than males. Other work reported areduction in Aβ, amyloid deposition, and amelioration of
cognitive deficits in 5XFAD/BACE1+/− mice, but did not
differentiate between the sexes [21-23]. We attribute the
elevated Aβ42 and amyloid deposition in female 5XFAD
to higher levels of APP transgene expression due to an es-
trogen response element (ERE) found in the Thy-1 pro-
moter of the transgene. The 5XFAD mouse model has
become quite widely used in the Alzheimer’s field, and this
study highlights the importance of using cohorts of the
same gender, or containing equal numbers of each sex. If
experimental and control groups are not gender balanced,
effects on cerebral Aβ and amyloid pathology may be ob-
served that are not due to experimental manipulation, but
to higher Aβ levels in female mice.
We hypothesize that the lower level of expression of
the APP transgene in 5XFAD males is the cause of the
decreased cerebral Aβ42 and amyloid, and leads to a
situation where BACE1 is in excess of APP, even when
reduced by 50%, so that no Aβ42 lowering occurs in
5XFAD/BACE1+/− mice. In contrast, because of higher
transgenic APP levels in 5XFAD females, BACE1 is not
in excess over APP, thus resulting in substantial Aβ42
lowering with 50% BACE1 reduction. These results sug-
gest that 50% BACE1 inhibition would be an effective
therapeutic approach to decreasing cerebral Aβ42 levels
only under conditions where BACE1 is not in excess
over APP. In the case of human AD patients, APP is not
overexpressed, and BACE1 is increased during the course
of disease, suggesting BACE1 is likely to be present in ex-
cess of APP, limiting the therapeutic efficacy of reducing
BACE1 activity by 50%. Finally, we also report an accurate,
simple, and inexpensive dot blot assay to measure cerebral
Aβ42 levels as an alternative to Aβ42 ELISA.
Results
BACE1 levels are consistently reduced by ~50% in
5XFAD/BACE1+/− mice at all ages and are the same in
both genders
Recent studies suggest that complete therapeutic inhib-
ition of BACE1 might be associated with complex neuro-
logical mechanism-based side effects (reviewed in [8,9]).
Therefore, partial BACE1 inhibition might offer a safer
therapeutic option, provided enough BACE1 inhibition
can be achieved to significantly reduce Aβ42 production
in the brain. The goals of the present study were to deter-
mine 1) the extent to which partial BACE1 inhibition
lowers brain Aβ42 levels, 2) establish an accurate cost-
effective Aβ42 dot blot assay as an alternative to Aβ42
ELISA. To accomplish these goals, we modeled partial
BACE1 inhibition by crossing BACE1−/− mice [3,5,11]
with 5XFAD transgenic mice that exhibit aggressive,
early-onset amyloid pathology [27]. 5XFAD offspring that
were BACE1+/+, +/−, or −/− were aged to 4, 6, and 9 months
of age and brains analyzed for BACE1, Aβ42, APP, and
Sadleir et al. Molecular Neurodegeneration 2015, 10:1 Page 3 of 16
http://www.molecularneurodegeneration.com/content/10/1/1BACE1-cleaved APP fragments. We analyzed females and
males separately in all experiments because our initial
characterization of 5XFAD mice [27] and subsequent work
showed that females accumulate higher levels of cerebral
Aβ42 on average than males. Initially, we measured
BACE1 levels in homogenates of hemibrains from these
mice by immunoblot analysis using the monospecific anti-
BACE1 antibody BACE-Cat1 [28]. As expected, at all ages
5XFAD/BACE1+/− mice have ~50% of the BACE1 level ex-
hibited by 5XFAD/BACE1+/+ mice (Figure 1). Moreover,
for a given BACE1 genotype, females and males have the
same level of BACE1, demonstrating that increased accu-
mulation of cerebral Aβ42 in females is not the result of
elevated BACE1. For this analysis, and all subsequent ana-
lyses of the 5XFAD/BACE1 mice, we analyzed 6 to 17 ani-
mals for each age/genotype/sex combination, as described
in detail in the Methods.
Dot blot with an Aβ42-selective antibody effectively
measures Aβ42 levels in 5XFAD brain homogenates
We next endeavored to investigate the effect of a 50% re-
duction in BACE1 on Aβ42 level in 5XFAD mice. Com-
mercial sandwich ELISAs that measure Aβ42 levels are
accurate and sensitive but expensive, thus limiting their
use. Therefore, we developed a simple, robust, and accurate
Aβ42 dot blot assay as a cost-effective alternative to com-
mercial ELISAs for measuring levels of Aβ42 in APP trans-
genic mouse and human AD brain. To validate the Aβ42
dot blot assay, we prepared guanine hydrochloride ex-
tracted brain homogenates from small cohorts of the fol-
lowing genotypes of 6 month old mice: non-transgenic
(non-Tg)/BACE1−/−, non-Tg/BACE1+/+, 5XFAD/BACE1−/−,
5XFAD/BACE1+/−, 5XFAD/BACE1+/+ (n = 6, except non-
Tg/BACE1−/−, n = 2). Homogenates were dotted in triplicate
onto a nitrocellulose membrane that was incubated with
rabbit anti-Aβ42 C-terminal selective antibody followed by
goat anti-rabbit-HRP secondary antibody and chemilumin-
escence detection (Figure 2A). Quantification of dot blot
signals revealed that Aβ42 was not detectable in non-Tg/
BACE1−/− brain homogenates (Figure 2B), as expected from
previous studies [5,10]. Non-Tg/BACE1+/+ homogenates
also showed no Aβ42 signal above background, indicating
that the dot blot assay is not sensitive enough to detect en-
dogenous mouse Aβ42. 5XFAD/BACE1−/− homogenates
had a minor Aβ42 signal that was not significantly different
than that for non-Tg/BACE1+/+ homogenate. This small
5XFAD/BACE1−/− signal is likely derived from α-secretase
cleaved p3 fragment ending in Aβ amino acid 42 (p3(42))
that is overproduced because of transgenic APP overex-
pression and demonstrates that the anti-Aβ42 C-terminal
selective antibody does not recognize full-length APP.
5XFAD/BACE1+/+ and 5XFAD/BACE1+/− homogenates
both exhibited robust Aβ42 signals with 5XFAD/BACE1+/−
having about half the signal of 5XFAD/BACE1+/+.We further assessed the dynamic range of the Aβ42 dot
blot technique by comparing 5XFAD/BACE1+/+ females at
4, 6 and 9 months (n = 6) to non-Tg/BACE1+/+ females at
6 months (n = 6) and to non-Tg/BACE1−/− females (n = 2)
(Figure 2C, D). These groups were easily distinguished and
signals were detected over at least a ~10-fold dynamic
range (between the 4 month and 9 month 5XFAD female
mice). Again the non-Tg/BACE1+/+ signals were near
background, indicating that the dot blot cannot detect en-
dogenous mouse Aβ42.
Inactivating one BACE1 allele reduces Aβ42 level and
amyloidosis in female but not male 5XFAD mice
Next, we used the Aβ42 dot blot assay to assess the
effects of BACE1 reduction on cerebral Aβ42 levels in
larger cohorts of female and male 5XFAD mice at 4, 6
and 9 months of age (Figure 3A-C; n = 6-17 per sex per
genotype per age). We observed a significant ~30-40%
reduction in Aβ42 level in 5XFAD/BACE1+/− females
compared to 5XFAD/BACE1+/+ females at all ages. Sur-
prisingly, male 5XFAD/BACE1+/− mice failed to exhibit
any Aβ42 reduction compared to 5XFAD/BACE1+/+
males at any age. Notably, female 5XFAD/BACE1+/+
mice displayed markedly higher cerebral Aβ42 levels
than male 5XFAD mice of either BACE1+/− or BACE1+/+
genotypes at all ages, while female 5XFAD/BACE1+/−
mice had significantly higher Aβ42 levels than males
only at 4 months of age (p = 0.001). These results dem-
onstrate the existence of significant gender differences in
the ability of the BACE1+/− genotype to reduce Aβ42
levels in the brains of 5XFAD mice.
We further verified these results by measuring cerebral
Aβ42 in the brains of the 6-month old mice by commercial
Aβ42 sandwich ELISA (Figure 3D). As before, we noted a
significant ~30% decrease in Aβ42 in 5XFAD/BACE1+/−
compared to 5XFAD/BACE1+/+ females, but no difference
between 5XFAD/BACE1+/− and 5XFAD/BACE1+/+ males,
corroborating our Aβ42 dot blot results. Aβ42 levels mea-
sured by dot blot correlated well with Aβ42 measured by
ELISA (Figure 3E), further validating the dot blot assay as
a simple, inexpensive, and accurate technique for relative
quantifications of cerebral Aβ42.
To determine the sensitivity and dynamic range of the
dot blot method, synthetic human Aβ42 was resuspended
in DMSO, diluted in 4 mM HEPES, and spiked into a
brain homogenate from a transgene-negative BACE1−/−
mouse (which lacks endogenous Aβ) at 2-fold concentra-
tion steps, always maintaining total protein concentration
at 10 mg/ml. These preparations were then extracted in
GuHCl and subjected to Aβ42 dot blot analysis as for the
5XFAD brain homogenates (Figure 3F). We observed that
the dot blot assay remains accurate and nearly linear over
at least a 500-fold range from 1.9 to 1000 ng of synthetic
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Figure 1 BACE1 levels are reduced by ~50% in 5XFAD/
BACE1+/− mice. (A) 20 μg of protein/lane of brain homogenates of
4, 6, and 9 month-old 5XFAD/BACE1+/+, 5XFAD/BACE1+/− or 5XFAD/
BACE1−/− (as a negative control) female (F) and male (M) mice were
separated by SDS-PAGE, transferred onto PVDF membrane, stained
with Ponceau S, and incubated with BACE-Cat1 monospecific
antibody against BACE1 [28] followed by HRP-conjugated secondary
antibody and chemiluminescence imaging. Representative BACE1
immunoblot and Ponceau S staining of brain homogenates from
4 month-old mice is shown. Note the absence of BACE1 immunosignal
in the BACE1−/− lane. (B-D) Relative quantification of BACE1 levels in
brain homogenates of 4, 6, and 9 month-old female and male
5XFAD/BACE1+/+, 5XFAD/BACE1+/− or 5XFAD/BACE1−/− mice. BACE1
immunosignals were normalized to Ponceau S staining intensity per
lane, averaged for each group, then presented as percentage of mean
female 5XFAD/BACE1+/+ BACE1 level. At all ages, BACE1 level is
significantly reduced by ~50% in 5XFAD/BACE1+/− mice compared to
5XFAD/BACE1+/+ mice, and there is no difference in BACE1 level
between male and female 5XFAD/BACE1+/+ or male and female
5XFAD/BACE1+/− mice.
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1000 ng Aβ42, the curve is best fit by a second order poly-
nomial function. We have used the same dot blot method
to measure Aβ42 ranging from 1.5-30 ng/mg total protein
in brain homogenates of cognitively normal, aged humans
[29], and ranging from 50–275 ng/mg total protein in
5XFAD brain homogenates (Figure 3E). In these ranges,
the assay shows a very linear (R2 = 0.9966) relationship
between Aβ42 concentration and dot blot signal intensity
(Figure 3G, inset). Thus, the dot blot assay is sensitive and
linear in the range needed to measure Aβ42 in the brains
of 5XFAD mice, other mouse models of AD, and aged
humans.
Based on the biochemical findings described above, we
anticipated a decrease in the Aβ42 plaque load in
5XFAD/BACE1+/− females compared to 5XFAD/BACE1+/+
females, and in both the 5XFAD/BACE1+/+ and 5XFAD/
BACE1+/− males compared to 5XFAD/BACE1+/+ females.
To investigate this, we co-immunostained brain sections
from 6-month old male and female mice of the above
genotypes with antibodies against Aβ (clone 3D6) and
BACE1, then imaged the sections by immunofluorescence
confocal microscopy (Figure 4). As expected, qualitative
inspection of representative images indicated that female
5XFAD/BACE1+/− mice have a reduction in size and num-
ber of amyloid plaques throughout Layer 5 cortex and
hippocampus compared to female 5XFAD/BACE1+/+ mice.
As suggested by Aβ42 dot blot and ELISA measurements,
5XFAD/BACE1+/+ and 5XFAD/BACE1+/− male mice ap-
peared to have similar sizes and numbers of plaques and
both have many fewer plaques than 5XFAD/BACE1+/+
females. BACE1 immunostaining was visible in a halo of
dystrophic neurites around plaques in all 5XFAD mice
[28,30], although peri-plaque BACE1 fluorescence intensity
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Figure 2 Dot blot assay effectively measures relative levels of cerebral Aβ42. (A) Validation of blot assay. Brain homogenates from 6
month-old female mice were extracted overnight in GuHCl, then spotted in triplicate on nitrocellulose membrane, dried, stained with Ponceau S,
and incubated with anti-Aβ42 antibody followed by HRP-conjugated secondary antibody and chemiluminescence imaging. To subtract non-specific
background, a duplicate membrane was prepared in the same way, except that the anti-Aβ42 primary antibody was not included (secondary only).
(+) or (−) indicate 5XFAD or non-transgenic genotypes, respectively; BACE1 genotype is indicated below 5XFAD genotype. (B) Relative quantification
of the Aβ42 dot blot in (A). The secondary only background was subtracted from the Aβ42 immunosignal, then the difference was normalized to
Ponceau S staining intensity and triplicates averaged. Group means were calculated and presented as percentages of the 5XFAD/BACE1+/+ female
group. The Aβ42 level in 5XFAD/BACE1−/− females is not significantly different than that of non-Tg BACE1+/+ females, indicating that the anti-Aβ42
antibody does not recognize full-length APP. 5XFAD/BACE1+/− mice have significantly less Aβ42 than 5XFAD/BACE1+/+ mice and significantly more
Aβ42 than 5XFAD/BACE1−/− mice. n = 6 per genotype, except n = 2 for non-Tg/BACE1−/−. (C) Aβ42 dot blot demonstrating the dynamic range of the
assay. Brain homogenates from female 4, 6, and 9 month-old 5XFAD/BACE1+/+ (n = 6), 6 month-old non-Tg BACE1+/+ (n = 6), and BACE1−/− (n = 2)
mice were prepared as in (A), except homogenates were extracted in GuHCl for 72 rather than 24 hrs, which eliminated the IgG background. Since
there was no secondary only signal, this blot is not shown, or used for correction. (D) Relative quantification of the Aβ42 dot blot in (C) shows at least
a 10-fold dynamic range of detection, and clear differences are observed between groups.
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level results in less BACE1 accumulation in dystrophic
neurites around plaques, and is associated with reduced
amyloid deposition, at least in female 5XFAD/BACE1+/−
mice.
Taken together, our biochemical and immunofluores-
cence microscopy results indicate that 50% BACE1 re-
duction in 5XFAD mice decreases cerebral Aβ42 level
and amyloid plaque load in female, but not male, mice.
Additionally, female 5XFAD mice exhibit higher levels of
Aβ42 and plaques compared to males, at least for the
5XFAD/BACE1+/+ genotype.
Relative levels of BACE1-cleaved APP fragments sAPPβ
and C99 frequently parallel levels of Aβ42 and amyloid
deposition in 5XFAD/BACE1+/+ and 5XFAD/BACE1+/− mice
We wished to gain further insight into the basis of the
difference in Aβ42 levels between 5XFAD/BACE1+/+
males and females, and the lack of effect of BACE1 het-
erozygosity on Aβ42 in males, by measuring the direct
products of BACE1 cleavage of APP: the ~100 kDa
secreted N-terminal fragment, sAPPβ, and ~11 kDa
membrane-bound C-terminal fragment C99. Differences
in levels of cerebral Aβ42 and amyloid plaques could
arise from variations in Aβ42 production, clearance, or
both. Parallel patterns of relative levels of Aβ42, sAPPβ,
and C99 in 5XFAD brains would support the conclusion
that differences in Aβ42 levels are the result of varia-
tions in BACE1 cleavage of APP, not Aβ42 clearance. In
contrast, divergent patterns of Aβ42, sAPPβ, and C99
levels could indicate different degrees of Aβ42 clearance
without changes in Aβ42 production rates. To investi-
gate these alternative scenarios, we quantified levels of
sAPPβ and C99 via immunoblot analysis (Figure 5,
n = 6–17 per sex per genotype per age). In general, the
patterns of levels for both sAPPβ and C99 were similar
to those seen for Aβ42 for the different genotypes, gen-
ders, and ages of 5XFAD mice. A trend toward reduced
levels of sAPPβ were observed at 6 and 9 months of agein female 5XFAD/BACE1+/− compared to female 5XFAD/
BACE1+/+, but these differences failed to reach statistical
significance (Figure 5C and D). As with Aβ42, no dif-
ference in sAPPβ level was seen between males of either
genotype. Again like Aβ42, 5XFAD/BACE1+/+ and
5XFAD/BACE1+/− males exhibited a significant ~40-50%
reduction in sAPPβ compared to 5XFAD/BACE1+/+ fe-
males at 6 and 9 months of age. Unlike Aβ42, no signifi-
cant differences in sAPPβ levels were observed between
the different genotypes or genders of 5XFAD mice at
4 months of age. Results similar to those of sAPPβ and
Aβ42 were obtained for levels of C99 in 5XFAD brains
(Figure 5F-H). We observed that female 5XFAD/BACE1+/−
have lower C99 levels than female 5XFAD/BACE1+/+ mice.
Athough non-significant trends were seen at 6 and
9 months, the C99 decrease was statistically significant at
4 months (Figure 5E-H). Also recapitulating the pattern of
sAPPβ and Aβ42, there was no difference between C99
levels in 5XFAD/BACE1+/− and 5XFAD/BACE1+/+ males,
but both have on average only ~50% of the C99 level in
5XFAD/BACE1+/+ females.
Although some of the differences in sAPPβ and C99
between 5XFAD/BACE1+/+ and 5XFAD/BACE1+/− fe-
males failed to reach statistical significance, there were
decreases in both cleavage products at all time-points in
the female 5XFAD/BACE1+/−, except for 4 month sAPPβ
levels. In contrast, male 5XFAD/BACE1+/− mice never
showed reductions in sAPPβ and C99 compared to male
5XFAD/BACE1+/+ mice. Because sAPPβ and C99 immu-
noblots were only semi-quantitative and had notable
background leading to high variability, statistical signifi-
cance was not achieved in some cases. In contrast, Aβ42
dot blots had much lower background and each sample
was measured in triplicate, greatly reducing variability
and improving the ability to achieve statistically signifi-
cant results. When both significant differences and non-
significant trends were considered, the general patterns
of relative quantifications of Aβ42, sAPPβ, and C99 par-
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Figure 3 Aβ42 levels are reduced in female but not male 5XFAD/BACE1+/− mice. (A-C) Aβ42 dot blot assays were performed using GuHCl
extracted brain homogenates from 4 (A), 6 (B) and 9 (C) month-old 5XFAD/BACE1+/+ and 5XFAD/BACE1+/− male and female mice (n = 6–17
mice per genotype per sex) and relative quantifications determined and presented as percentages of the mean female 5XFAD/BACE1+/+ Aβ42
level. 5XFAD/BACE1+/− females had ~30-40% less Aβ42 than 5XFAD/BACE1+/+ females. In contrast, Aβ42 levels of male 5XFAD/BACE1+/− and
5XFAD/BACE1+/+ were indistinguishable, and both were significantly less than that of 5XFAD/BACE1+/+ females. (D) To confirm the relative Aβ42
quantifications generated by the dot blot assay, Aβ42 levels in the brain homogenates from the 6 month-old cohort shown in (B) were quantified
by commercial Aβ42 ELISA (Invitrogen), yielding very similar results. (E) Aβ42 measured by ELISA correlates significantly with Aβ42 measured by
dot blot, further validating this method. (F) To determine the range and sensitivity of the Aβ42 dot blot assay, known quantities of synthetic
Aβ42 were spiked into a transgene-negative BACE1−/− homogenate, which was then GuHCl extracted and analyzed by dot blot (upper blot).
Numbers above the blot indicate concentrations of Aβ42 in ng/mg total brain homogenate protein. (G) Aβ42 dot blot signals from (F) were
corrected by subtracting the secondary antibody-alone background, converted to percentage of intensity of 1000 ng Aβ42/mg protein (y-axis),
and plotted as a function of known Aβ42 concentration (x-axis). The dot blot is accurate through at least a 500-fold concentration range, with
very good linearity from 1.9-250 ng Aβ42/mg total protein, as shown by the blue section of the curve (expanded in the inset). Error bars (SEM)
are plotted in both graphs, but are too small to be seen except in the expanded inset.
Sadleir et al. Molecular Neurodegeneration 2015, 10:1 Page 7 of 16
http://www.molecularneurodegeneration.com/content/10/1/1
5XFAD BACE1+/+ F 5XFAD BACE1+/+ M




Figure 4 Amyloid plaques are reduced in female but not male 5XFAD/BACE1+/− mice. Free-floating 30 μm brain sections from 6 month-old
male and female 5XFAD/BACE1+/+ and 5XFAD/BACE1+/− mice were co-stained with clone 3D6, an antibody to the N-terminus of Aβ (green),
anti-BACE1 antibody (red), and DAPI (blue) and imaged by fluorescence confocal microscopy. Three mice of each sex and genotype combination were
analyzed for a total of twelve mice, and all images were captured using identical confocal camera and laser configurations. The representative images
of mid-dorsal cortex and hippocampus shown here are from individuals that had Aβ42 dot blot values near the mean of each group. Amyloid plaque
densities in Layer 5 of the cortex correlate well with Aβ42 levels determined by dot blot. Female 5XFAD/BACE1+/+ mice have the highest plaque
density, with 5XFAD/BACE1+/− females showing a marked reduction in amyloid deposits by comparison. In contrast, male 5XFAD/BACE1+/+ and
5XFAD/BACE1+/− mice had similar plaque densities, and both had fewer plaques than 5XFAD/BACE1+/+ female mice. These histological results support
our biochemical data showing that Aβ42 levels are reduced in 5XFAD/BACE1+/− female, but not male, mice (Figure 3). Size bar represents 100 μm.
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from altered clearance rates or other mechanisms, we
interpret these data to suggest that the reduced Aβ42
level of 5XFAD/BACE1+/− females compared to 5XFAD/
BACE1+/+ females is likely due to decreased BACE1
cleavage of APP. Similarly, the reduced C99 and sAPPβ in
5XFAD/BACE1+/+ males compared to 5XFAD/BACE1+/+
females suggest that the lower levels of Aβ42 and amyloid
deposition in 5XFAD/BACE1+/+ males is also due to de-
creased BACE1 cleavage of APP. Since BACE1 levels were
similar in males and females of the same genotype at 4, 6
and 9 months (Figure 1), we hypothesized that APPtransgene expression may vary between male and female
5XFAD mice.
Transgenic APP level is increased and correlates with
elevated Aβ42 in 5XFAD female mice
One potential reason for increased cerebral Aβ42 accu-
mulation, and increased levels of APP cleavage products
C99 and sAPPβ in female 5XFAD mice could involve
higher female expression of the APP transgene. To in-
vestigate this possibility, we performed immunoblot ana-
lysis with an anti-APP antibody specific to human APP
(clone 6E10) to measure the steady-state levels of
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Figure 5 BACE1-cleaved APP fragments sAPPβ and C99 are reduced in female but not male 5XFAD/BACE1+/− mice. (A) Representative
sAPPβ immunoblot and Ponceau S staining of brain homogenates from 4 month-old male (M) and female (F) mice. Note the minimal sAPPβ
signal in the 5XFAD/BACE1−/− lane; residual band likely results from minor cross-reactivity to sAPPα. (B-D) Relative quantifications of sAPPβ
immunoblot signals from 5XFAD/BACE1+/+ and 5XFAD/BACE1+/− mice. At 4 months of age there is no statistical difference in sAPPβ levels
between the sexes or genotypes. However, at 6 and 9 months of age 5XFAD/BACE1+/− females show trends toward lower sAPPβ levels than
5XFAD/BACE1+/+ females, mirroring the significant reduction in Aβ42 levels. sAPPβ levels in 6 and 9 month-old 5XFAD/BACE1+/− and 5XFAD/
BACE1+/+ male are indistinguishable, and significantly less than in 5XFAD/BACE1+/+ females. (E) Representative of C99 immunoblot and Ponceau
S staining of brain homogenates from 9 month-old male (M) and female (F) mice. The doublet bands reflect the phosphorylation state of the
APP C-terminal fragments. The lower doublet represents the α-secretase-cleaved APP C-terminal fragment C83. Note the absence of the C99
signal in the 5XFAD/BACE1−/− lane. (F-H) Relative quantification of C99 immunoblot signals from male and female 5XFAD/BACE1+/+ and 5XFAD/
BACE1+/− mice. At all ages, 5XFAD/BACE1+/− females have lower levels of C99 than 5XFAD/BACE1+/+ females, but this difference reaches statistical
significance only at 4 months. In contrast, C99 levels are not significantly different between 5XFAD/BACE1+/+ and 5XFAD/BACE1+/− males at any
age. At 4 and 6 months of age, 5XFAD/BACE1+/+ males have significantly less C99 than 5XFAD/BACE1+/+ females, but at 9 months the decrease
does not reach statistical significance due to large variation in the female cohort. Overall, the patterns of sAPPβ and C99 levels correlate with
those of Aβ42 levels for the different genotypes and genders.
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5XFAD mice analyzed for Aβ42 by dot blot assay
(Figure 6A-D, n = 6–17 per sex per genotype per age).
We observed that at all ages 1) female 5XFAD/BACE1+/+
mice have ~30-40% higher levels of APP than male
5XFAD/BACE1+/+, 2) female 5XFAD/BACE1+/− mice ex-
hibit ~30-40% higher levels of APP than male 5XFAD/
BACE1+/−, and 3) APP levels in 5XFAD/BACE1+/− mice
are significantly higher than those in 5XFAD/BACE1+/+mice for both genders. The first two findings demonstrate
that transgenic APP levels are markedly elevated in female
compared to male 5XFAD mice when we control for
BACE1 genotype. The third finding is consistent with the
hypothesis that 50% BACE1 level in 5XFAD/BACE1+/−
mice results in reduced BACE1 cleavage of APP that
causes elevated steady-state APP levels, and that α-
secretase processing of APP cannot fully compensate for
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Figure 6 (See legend on next page.)
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Figure 6 Female 5XFAD mice of either BACE1+/+ or BACE1+/− genotypes have higher steady-state transgenic APP levels than males.
(A) Representative transgenic APP immunoblot (6E10) and Ponceau S staining of brain homogenates from 4 month old male (M) and female (F)
mice. Note the high level of APP in the 5XFAD/BACE1−/− lane. (B-D) Relative quantifications of transgenic APP immunoblot signals. At all ages,
steady-state transgenic APP levels are higher in 5XFAD/BACE1+/− and 5XFAD/BACE1+/+ females than in corresponding males. Additionally, there is
a trend toward higher transgenic APP levels in 5XFAD/BACE1+/− compared to 5XFAD/BACE1+/+ mice that becomes significant at 9 months, which
could result from less BACE1 cleavage in the BACE1+/− genotype. (E) Representative APP immunoblot (C-terminal APP antibody) and Ponceau S
staining of brain homogenates from 6 month old 5XFAD/BACE1+/+ (+) and non-Tg/BACE1+/+ (−) mice to measure both human and mouse APP.
(F) Relative quantifications of APP immunoblot signals in (E) demonstrates that while non-Tg males and females have equal levels of endogenous
APP, 5XFAD females have significantly higher APP levels than 5XFAD males, a result that is consistent with the 6E10 immunoblot data showing
elevated transgenic APP levels in 5XFAD females. n = 9–14 mice per sex per genotype. (G) Schematic diagram of murine Thy-1 promoter transgene
cassette with 5’ upstream sequence showing estrogen resonse element (ERE). The APP or PS1 coding regions are inserted into the XhoI site. Thy-1
gene exons are shaded blue. Base-pair (bp) numbering is relative to the transcriptional start site for Thy-1 exon 1a [32]. The ERE is located from −1116
bp to −1104 bp in the 5’ upstream regulatory region of the Thy-1 promoter. The one bp deviation of the Thy-1 ERE at position +6 could be overcome
by the flanking A-T rich sequence, which enhances ERE transcriptional potency in vivo [33].
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there is no BACE1 cleavage of APP and steady-state APP
levels are at their highest [6] (Figure 6A).
To verify our APP immunoblot results obtained with
the 6E10 antibody, we estimated the levels of transgenic
APP compared to endogenous APP using an antibody
that recognizes the C-terminus of both mouse and hu-
man APP (Figure 6E). When brain homogenates from
6-month old non-Tg and 5XFAD mice (n = 9–14 per sex
per genotype) were subjected to immunoblot analysis
with the APP C-terminal antibody, we found that female
5XFAD mice have ~200% of the APP level found in
non-Tg females, while male 5XFAD mice have ~160% of
the female non-Tg APP level (Figure 6F). In contrast,
there was no significant difference in levels of endo-
genous APP between non-Tg males and females. When
the immunoblot signal representing endogenous APP is
subtracted, female 5XFAD mice have ~40% higher
steady-state transgenic APP levels than 5XFAD males, in
good agreement with the female ~30-40% elevations ob-
served with the human APP-specific antibody 6E10. We
conclude that the increased steady-state level of trans-
genic APP in female 5XFAD mice likely has a role in ele-
vated cerebral Aβ42 accumulation in 5XFAD females
compared to males.
The difference in transgenic APP level observed bet-
ween male and female 5XFAD mice could be due to
gender differences in APP transgene transcription or
translation, mRNA or protein stability, or some post-
translational modification or other process. Since steady-
state levels of endogenous APP do not appear to differ
between male and female non-Tg mice, it appeared un-
likely that gender-specific alterations in expression or
stability exist, at least for endogenous APP. Therefore,
we reasoned that the higher 5XFAD female transgenic
APP level is more likely the result of a gender difference
in transgene expression due to an effect of the murine
Thy-1 promoter cassette [31] that drives APP transgene
transcription, or from the chromosomal locus intowhich the transgene has integrated. If the transgene
Thy-1 promoter is responsible, then one might predict
the presence of an estrogen responsive element (ERE) in
the 5′ upstream regulatory region of the 5XFAD trans-
gene. Indeed, inspection of the Thy-1 regulatory se-
quence found in the Thy-1 transgene cassette (GenBank
accession AC126459.3, nucleotides 7732–11902, reverse
complement) revealed an ERE at base pairs −1116
to −1104 relative to the transcriptional start site of Thy-
1 exon 1a [32], however this ERE exhibited a single nu-
cleotide change from the consensus ERE at position +6
(Figure 6G). Although the Thy-1 promoter ERE is im-
perfect, it is surrounded by A-T rich sequence, which is
predicted to increase ERE transcriptional activity [33].
Thus, although we cannot presently exclude other po-
tential mechanisms, the presence of the ERE in the APP
transgene promoter is likely to explain elevated trans-
genic APP levels in female compared to male 5XFAD
mice.
Discussion
Here, we report that 50% BACE1 reduction lowers cere-
bral Aβ42 levels by ~30-40% in female, but not male,
5XFAD/BACE1+/− mice. Similarly, 50% BACE1 reduc-
tion lowers sAPPβ and C99 levels in female 5XFAD/
BACE1+/− mice, paralleling the Aβ42 decrease and sug-
gesting reduced BACE1 cleavage of APP, although other
mechanisms such as increased Aβ42 clearance remain
formally possible. We also show that female 5XFAD
mice have higher cerebral Aβ42 levels than males, which
is most pronounced in the BACE1+/+ genetic back-
ground and correlates with higher steady state trans-
genic APP levels in female compared to male 5XFAD
mice. Importantly, an ERE exists in the neuron-specific
5XFAD transgene murine Thy-1 promoter sequence,
which potentially could explain the increased transgenic
APP level and, in turn, the higher cerebral Aβ42 accu-
mulation in female 5XFAD mice [27]. Finally, we report
a robust and accurate Aβ42 dot blot assay for measuring
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native to Aβ42 ELISA. Together, these results reveal that
the effectiveness of 50% BACE1 inhibition in reducing
cerebral Aβ42 is affected by relative levels of BACE1 and
APP, which has important implications for use of BACE1
inhibition in preventing or treating AD.
We have previously reported that our dot blot assay
can measure Aβ42 in the brains of cognitively normal,
aged humans, with results comparable to those ge-
nerated by ELISA [29]. By ELISA, Aβ42 varied from
1.5-30 ng/mg total protein in homogenates of normal
human brains, which is in the linear range of our dot
blot method. Here we demonstrate that the dynamic
range of the Aβ42 dot blot assay is at least 500 fold, and
it is sensitive and linear in the range required for mea-
suring Aβ42 in the 5XFAD mouse model as well
(Figure 3G). This dot blot assay can be easily adapted to
measure absolute Aβ42 levels by including known quan-
tities of synthetic Aβ42 on the dot blot for generating a
standard curve. The range of the standards for a com-
monly used commercial Aβ42 sandwich ELISA (e.g.,
Wako, Inc.) is 4-400 pg/ml, while the standards we used
for the dot blot assay range from 7.7-3900 ng/ml. While
the ELISA has the ability to detect very low concentra-
tions of Aβ42, as with plasma or cerebral spinal fluid
samples, this is not necessarily advantageous for samples
with high Aβ42 concentrations, such as brain homoge-
nates of APP transgenic mice or aged humans, because
they have to be diluted up to 5000-fold, leaving room for
pipetting error, while the dot blot assay requires little if
any dilution, and is thus potentially less error-prone.
Additionally, the linear range of the ELISA readout is
only around 100-fold, while our dot blot is 500 fold,
allowing the comparison of diverse samples. In short, we
suggest the dot blot technique for measuring Aβ42 levels
in brain homogenates of mouse models of AD and in
human subjects, though it is likely to be less sensitive
for measuring low concentrations of Aβ42 in samples
such as cerebral spinal fluid or plasma.
The findings reported here are congruous with those
of other studies showing reduced Aβ and amyloid path-
ology in APP transgenic mice with one inactive allele of
BACE1 [5,14,21-26]. The degree of Aβ lowering with
50% BACE1 reduction varies depending on the study,
which might be related to differences in the APP trans-
genic mouse models employed, such as APP mutation,
overexpression level, and strain background, among
others. The level of Aβ lowering in female 5XFAD/
BACE1+/− mice in our study was most similar to that
observed in APPSwe/PS1E9/BACE1+/− mice, in which
Aβ42 levels are decreased by 40% and 27% at 3 and
12 months, respectively [14].
Our observation that 50% BACE1 reduction in the
5XFAD transgenic line decreases Aβ42 levels in femalesonly was unexpected. Previous studies of BACE1+/− mice
on various APP transgenic backgrounds reported no dif-
ferences in Aβ levels between males and females [14,26]
or did not analyze the genders separately [21-24]. The
reason for the lack of Aβ42 lowering in male 5XFAD/
BACE1+/− mice remains enigmatic, although it might in-
volve the lower level of expression of the human APP
transgene in male compared to female 5XFAD mice. We
hypothesize that even with 50% BACE1 reduction in
male 5XFAD/BACE1+/− mice, BACE1 levels are still suf-
ficiently in excess of those of APP in the intracellular
compartments where β-secretase processing occurs such
that the same amount of APP can be cleaved as in male
5XFAD/BACE1+/+ mice. In contrast, in female 5XFAD/
BACE1+/− mice, BACE1 levels might not be in excess of
those of APP because of the higher female expression of
the APP transgene. This could render BACE1 rate-
limiting, so that at the 50% level BACE1 cleaves less
APP within β-secretase intracellular compartments, lea-
ding to a reduction in Aβ42, C99, and sAPPβ in 5XFAD/
BACE1+/− compared to 5XFAD/BACE1+/+ females. This
notion is supported by studies showing that PDAPP/
BACE1+/− mice with very high (~10 fold) APP transgene
expression [34] have 90% reduction in Aβ at 13 months
and 50% reduction at 18 months [24], while decreases in
endogenous Aβ are small in non-Tg BACE1+/− mice lac-
king an overexpressed APP transgene [25,26]. However,
contrary to the above argument, we also observed that in
both males and females, full-length transgenic APP levels
are significantly increased in 5XFAD/BACE1+/− compared
to 5XFAD/BACE1+/+ mice at 9 months of age, and trend
higher at the younger ages, regardless of gender, indicating
reduced β-secretase cleavage of APP in 5XFAD/BACE1+/−
of both sexes. Thus, there may be additional factors other
than transgenic APP level causing the difference in Aβ
lowering between male and female 5XFAD/BACE1+/−
mice.
These data, along with our current findings suggest
that the degree to which BACE1 activity must be inhib-
ited to significantly reduce cerebral Aβ42 levels will de-
pend on whether BACE1 is in excess of APP and by how
much. Depending of the study, in wild type mice, where
APP is not overexpressed, BACE1 heterozygosity has
either no effect on Aβ40 or Aβ42 [25] or reduces Aβ40
by ~10% [26]. In AD patients, BACE1 is elevated in dys-
trophic neurites surrounding plaques, as is APP [28,30],
so it difficult to determine whether BACE1 is in excess
of APP or not. BACE1 elevation in AD brains is de-
tectable by immunoblot and by enzymatic activities
[28,30,35,36] but APP elevation by immunoblot has not
been reported. The elevation of BACE1 protein levels
and enzymatic activity in AD brains suggests that
BACE1 could be in excess of APP, so we predict that
BACE1 inhibition greater than 50% will be required to
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BACE1 inhibitors in clinical trials are able to lower cere-
bral spinal fluid Aβ by ~50-90 % indicating highly effec-
tive BACE1 inhibition (reviewed in [9]), concerns about
mechanism-based side effects related to BACE1 over-
inhibition exist [8]. BACE1−/− mice have multiple com-
plex but subtle neurological abnormalities, though it is
not yet clear whether these stem from the absence of
BACE1 during crucial developmental periods, or during
adult life.
It should be noted that the presence of the APP Swedish
mutation in the 5XFAD mouse line could also affect the
degree to which 50% BACE1 reduction lowers Aβ42 ge-
neration, although probably not dramatically. This muta-
tion makes APP a better substrate for BACE1 [37] so a
larger proportion of APP molecules become cleaved to
produce Aβ. Rabe et al. [26] showed that heterozygous
BACE1 gene deletion reduces Aβ levels by 16% in mice
expressing a wild-type APP transgene, which more likely
reflects the situation in sporadic AD, and by 20% in mice
expressing an equivalent level of transgenic APP with the
Swedish mutation. Although 50% BACE1 reduction low-
ered Aβ levels in Swedish mutation APP mice greater than
in wild-type APP mice by a modest amount, these results
suggest the Swedish mutation does not dramatically alter
the effect of partial BACE1 reduction on Aβ generation, at
least in the mouse strains studied [26].
Our study furthers the characterization of the 5XFAD
mouse model, which is now widely used by the AD re-
search community, and highlights the variation between
males and females in this line. Differences between
males and females in Aβ levels and plaque deposition
have been reported in other mouse models of AD such
as the Tg2576, 3xTg-AD, and APPswe/PS1de9 lines
[38-40], and may be related to estrogen levels [41].
These results mirror observations in the human popula-
tion that AD risk is higher for females than males, even
after correcting for increased longevity [42], but it is still
not clear why women are more susceptible. Our obser-
vation that female 5XFAD mice have higher steady-state
levels of transgenic APP compared to males is likely re-
sponsible for increased female 5XFAD Aβ42 level and
amyloid deposition and appears to be related to the
presence of an ERE in the 5′ upstream regulatory region
of the murine Thy-1 transgene promoter. Levels of
endogenous APP did not differ between male and female
non-Tg mice, suggesting that female humans do not
have higher cerebral APP expression. Our results cau-
tion that the 5XFAD mouse and other AD transgenic
models that employ the Thy-1 promoter are not appro-
priate models for the gender disparity observed in AD.
Thus, a mechanism other than increased steady-state
APP level is likely responsible for the higher incidence
of AD in women. Additionally, these results illustratethe critical importance of designing studies in which the
control and experimental groups contain equal numbers
of males and females, and that data from the two gen-
ders should be analyzed separately to determine dif-
ferential effects of the experimental condition, and in
order to avoid false gender-specific differences. If gender
effects are observed in this model, or others using the
Thy-1 promoter, it is important to determine whether
the cause may be related to different levels of transgene
expression.
Conclusions
In summary, 50% BACE1 reduction in 5XFAD mice de-
creases cerebral Aβ42, plaque load, and BACE1-cleaved
fragments of APP in females but not males. Female
5XFAD mice express higher levels of transgenic APP,
probably because of an ERE in the Thy-1 transgene pro-
moter, which in turn likely explains elevated female
Aβ42. As a consequence of higher transgenic APP level,
we hypothesize that BACE1 level is not in excess of that
of APP in female 5XFAD mice, so that 50% BACE1 re-
duction significantly decreases Aβ42. In contrast, BACE1
could be in excess of APP in male 5XFAD mice, and as
a result 50% BACE1 reduction has little effect on lower-
ing Aβ42 levels. Since BACE1 is likely to be in excess of
APP in the human brain, we suggest that partial BACE1
inhibition should be greater than 50% to have thera-
peutic benefit for AD. Finally, our Aβ42 dot blot assay
offers an accurate, simple, and cost-effective alternative
to expensive commercial Aβ42 ELISAs.
Methods
Mice
5XFAD mice overexpress the K670N/M671L (Swedish),
I716V (Florida), and V717I (London) mutations in hu-
man APP(695), as well as M146L and L286V mutations
in human PS1. The generation of the 5XFAD mice has
been described previously [27]. These mice were crossed
to a BACE1−/− line generated as described [4,5]. All mice
were genotyped by PCR amplification of tail clip DNA.
Mice were euthanized by carbon dioxide inhalation. One
hemibrain was snap-frozen in liquid nitrogen. The other
hemibrain was drop fixed in 4% paraformaldehyde in
PBS for 16–20 hrs, then transferred to 30% w/v sucrose in
1×PBS with azide for storage. All animal work was done
in accordance with Northwestern University IACUC ap-
proval. The numbers of mice per age per sex per genotype
are as follows: 4 month female 5XFAD/BACE1+/−: 17;
4 month female 5XFAD/BACE1+/+: 7; 4 month male
5XFAD/BACE1+/−: 10; 4 month male 5XFAD/BACE1+/+:
12; 6 month female 5XFAD/BACE1+/−: 14; 6 month female
5XFAD/BACE1+/+: 9; 6 month male 5XFAD/BACE1+/−: 6;
6 month male 5XFAD/BACE1+/+: 12; 9 month female
5XFAD/BACE1+/−: 11; 9 month female 5XFAD/BACE1+/+:
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5XFAD/BACE1+/+: 16.
Immunoblots and ELISA
Snap frozen hemi-brains were homogenized in 1 ml
1×PBS with 1% Triton X-100 supplemented with protease
inhibitors (Calbiochem) and Halt Phosphatase Inhibitor
Cocktail (Thermo Scientific). Protein concentration was
quantified using BCA Assay (Pierce). Twenty micrograms
of brain homogenate were separated on 12% Tris-glycine
gels and protein was transferred to 0.45 μm PVDF mem-
brane. For C99, proteins were separated on 16% Tris-
Tricine gels using cathode buffer containing 200 mM Tris,
200 mM Tricine, 0.2% SDS, pH 8.3 and anode buffer
containing 100 mM Tris HCl, pH 8.9. Membranes were
Ponceau S-stained immediately after transfer, then probed
overnight with anti-BACE1 antibody (BACE-Cat1, Vassar
lab, 1:1000) [28], anti-APP (6E10, Covance #SIG-39320-
500 1:2000) anti-APP (C-terminal rabbit monoclonal,
Epitomics #1565-1, 1:5000) anti-sAPPβ (Beta-APPsw
1:1000, Vassar et al., 1999) in 5% milk, followed by
washing and a 1 hour incubation with secondary HRP-
conjugated anti-mouse or anti-rabbit secondary antibody
(Vector Labs, PI-2000 or PI-1000, 1:10,000). Blots were
visualized using Luminata Crescendo (Millipore), and sig-
nals were quantified using a Kodak Image Station 4000R.
All signals were normalized to Ponceau S staining. For
theses analyses, multiple gels were cut into horizontal
strips and stacked so all samples for a given protein were
transferred to a single piece of PVDF membrane. Putting
all samples (up to 50) on one membrane eliminated the
need to account for variation in transfer, antibody incuba-
tion and ECL application that can occur between blots.
Student’s two-tailed t-test were done using InStat software
(GraphPad Software, Inc., San Diego, CA) to compare
the following pairs: 5XFAD/BACE1+/+ females to
5XFAD/BACE1+/− females, 5XFAD/BACE1+/+ females
to 5XFAD/BACE1+/+ males, and 5XFAD/BACE1+/+ males
to 5XFAD/BACE1+/− males. For the bar graphs, lines with
stars indicate groups statistically compared by Student’s
t-test; * 0.05 > p > 0.01 ** 0.01 > p > 0.001 *** 0.001 >
p > 0.0001; Error bars = S.E.M.
For Aβ42 dot blots, 10 mg/ml brain homogenates were
extracted in 1.56 volumes of 8.2 M guanidine hy-
drochloride (GuHCl); 82 mM Tris HCl (pH 8.0) (5 M
GuHCl final) over one to three nights on a nutator. To
create the Aβ42 standard curve, HFIP lyophilized Aβ42
(rPeptide) was resuspended at 5 mM in DMSO, then
diluted to 100 μM in 4 mM HEPES, and spiked into
10 mg/ml transgene negative BACE1−/− brain homoge-
nates at 2-fold concentration steps ranging from 1.95 to
100 ng Aβ42/mg total protein. Standard curve samples
were then GuHCl extracted as described. For dot blots,
1 μl of GuHCl extracted sample (3.9 μg total protein)was spotted in triplicate on gridded nitrocellulose mem-
brane, dried one hour at 37°C, then stained with Pon-
ceau S. Two identical blots were made and incubated in
either 1:2500 anti-Aβ42 rabbit monoclonal antibody
(clone H31L21, Invitrogen, #700254) or 5% milk only
(primary delete), followed by HRP-conjugated secondary
antibody (Vector Labs, PI-1000). The duplicate blots in-
cubated with anti-Aβ42 antibody or primary delete were
developed together with Luminata Crescendo (Millipore)
or West Femto (Pierce) for standard curve, and imaged
simultaneously using the Kodak Image Station 4000R or
MyECL Imager (Thermo Scientific). No images with
saturated pixels were used for quantification. Aβ42 signals
were normalized to Ponceau S staining, and the triplicates
averaged, and statistics were performed as described
above. For ELISA, GuHCl extracted samples were diluted
1:1000, and Aβ42 ELISA performed according to manu-
facturer’s instructions (Invitrogen). Standard curve equa-
tions were generated in Excel, using intensities from
images with no saturated pixels. For the bar graphs, lines
with stars indicate groups statistically compared by Stu-
dent’s t-test; * 0.05 > p > 0.01 ** 0.01 > p > 0.001 *** 0.001 >
p > 0.0001; Error bars = S.E.M.
Immunofluorescence confocal microscopy
Paraformaldehyde-fixed brains were sectioned at 30 μm.
Free-floating sagittal (females) or coronal (males) sections
were treated with TBS-0.25% Triton X-100 with 16 mM
glycine for 60 minutes on a shaker. Sections were washed
in TBS, blocked in 5% donkey serum in TBS-0.25% Triton
X-100 for one hour, then washed 2x10 minutes in 1% BSA
in TBS-0.25% Triton X-100. Sections were incubated at
4°C on a shaker overnight with anti-Aβ 3D6 (mouse
monoclonal, 1:250, gift from Lisa McConlogue, Elan). The
following morning, anti-BACE1 (1:250, rabbit monoclonal,
Abcam ab108394) was added and the sections were incu-
bated an additional 2 hours at 37°C with shaking. The sec-
tions were washed 3 times with TBS then incubated for
1.5 hours at room temperature on a shaker with Invitro-
gen Alexa Fluor secondary antibodies at 1:250 (Donkey
anti-Rabbit 594 and donkey anti-mouse 488) and DAPI at
300 nM. The sections were then mounted on slides
and immediately cover-slipped using ProLong Gold
(Invitrogen). Confocal images were captured on a Nikon
(Tokyo, Japan) A1R confocal microscope with a 40x objec-
tive, and 12 images were stitched together using NIS Ele-
ments software to generate a larger field image. All images
were captured at same laser and software configurations.
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